



Universiteit
Leiden
The Netherlands

Breaking barriers: unraveling response mechanisms to immunotherapy in breast cancer

Blomberg, O.S.

Citation

Blomberg, O. S. (2024, January 11). *Breaking barriers: unraveling response mechanisms to immunotherapy in breast cancer*. Retrieved from <https://hdl.handle.net/1887/3677353>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)



Downloaded from: <https://hdl.handle.net/1887/3677353>

Note: To cite this publication please use the final published version (if applicable).

RESPONSE

RESISTANCE

NEW OPPORTUNITIES



Immune regulation of metastasis: mechanistic insights and therapeutic opportunities

Olga S. Blomberg^{1,*}, Lorenzo Spagnuolo^{1,*}, Karin E. de Visser^{1,#}

DISEASE MODELS & MECHANISMS. 2018 OCT 24;11(10):DMM036236

Affiliations

¹Division of Tumor Biology & Immunology, Oncode Institute, the Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands.

*These authors contributed equally

#Corresponding author

Abstract

Metastatic disease is the leading cause of death in cancer patients. Metastasis formation involves a cascade of events for which the underlying mechanisms are still poorly understood. During the metastatic cascade, cancer cells tightly interact with the immune system, and they influence each other, both in the tumor microenvironment and systemically. The crosstalk between cancer and immune cells adds another layer of complexity to our understanding of metastasis formation, but at the same time opens new therapeutic opportunities for cancer patients. The intensifying development of immunotherapeutic strategies calls for a better understanding of immune regulation of metastasis in order to maximize the therapeutic benefit for patients with metastatic disease. In this review and accompanying poster, we describe the main mechanisms of immune regulation of metastasis that have been reported to date, and present promising immunotherapeutic options that are currently available, or may become so in the near future, to tackle metastasis.

Keywords

Metastasis, inflammation, immunotherapy, (pre-)metastatic niche

Dual role of the immune system in cancer


Cancer is one of the leading causes of death worldwide, and the vast majority of cancer-related deaths are a consequence of metastasis. Patients with advanced metastatic disease are, with rare exception, incurable by current treatment options. The process that leads to metastasis is referred to as the metastatic cascade (see **poster**). Briefly, to escape from the primary tumor site, cancer cells have to invade the surrounding tissue and intravasate into blood or lymphatic vessels, from which they can then spread throughout the body. Metastasis results from subsequent cancer cell extravasation at distant sites, followed by successful local outgrowth.

Throughout metastasis formation, cancer cells interact with the immune system, which can modulate each step of the cascade. The notion of a close interplay between tumor and immune cells dates back to the 19th century, when Rudolf Virchow first observed leukocytes infiltrating malignant tissues and hypothesized that cancers originate from chronically inflamed sites¹. Conversely, the immune system's anti-tumor potential was first postulated at the end of the same century by William Coley, who noticed that a patient with an inoperable, recurring sarcoma was completely cured after a concurrent infection. Inspired by this case, he treated cancer patients with a mixture of killed bacteria, which later became known as Coley's toxin², obtaining impressive clinical results. Coley's toxin was indeed the first cancer immunotherapy approach in history. These early observations suggest how, in the context of cancer, the immune system plays a dual role, and that a tumor's fate depends on the balance between anti-tumor immunity and tumor-promoting inflammation.

Besides shaping the development and outgrowth of primary tumors (see **poster, panel 1, 'Primary tumor growth'**), the immune system influences various steps of the metastatic cascade. In renal cell carcinoma patients, for instance, circulating monocytes have pro-metastatic functions. Compared with monocytes from healthy donors, patient-derived monocytes showed increased capability to promote cancer cell invasion and angiogenesis³. In colorectal cancer patients, the infiltration of T cells in the primary tumor was associated with reduced probability of tumor dissemination, suggesting an anti-tumor role of the adaptive immune system in the early stages of the metastatic process⁴. Although research revealed some of the metastasis-modulating effects of the immune system, the complexity of metastasis formation and the scarcity of accurate tumor models that properly mimic the full metastatic cascade make research in this field challenging. In this review, we discuss the most important mechanisms of immune system-metastasis interactions described to date, with the overall aim to underline their complexity and to highlight how they could be exploited therapeutically.

Anti-tumor immunity

The cancer-immunity cycle, a complex sequence of interactions between multiple cell types, is required for the establishment of an efficient anti-tumor immune response⁵. To initiate this, cancer cells need to release tumor antigens, which are taken up by professional antigen-presenting cells, such as dendritic cells (DCs). When properly activated by local immuno-stimulatory signals, such as inflammatory cytokines or other factors released in the tumor microenvironment (TME), DCs migrate to tumor-



Abbreviations: Ang-2, angiopeptin 2; Arg-1, arginase 1; ATP, adenosine triphosphate; BMDC, bone marrow-derived cell; Bv8 (also known as PROX2), prokinetin; CAR T cell, chimeric antigen receptor T cell; CCL, chemokine (C-C motif) ligand; CCR, chemokine (C-C motif) receptor; CD11b, cluster of differentiation 11b; cKit (also known as KIT and SCF), SCF receptor; COX, cyclooxygenase; CSF-1, colony-stimulating factor 1; CSF-1R, CSF-1 receptor; CTC, circulating tumor cell; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; CXCL, chemokine (C-X-C motif) ligand; CXCR, chemokine



(C-X-C-motif) receptor; ECM, extracellular matrix; EGF, epidermal growth factor; EGFR, EGF receptor; G-CSF, granulocyte-colony stimulating factor; G-CSFR, G-CSF receptor; dTR, glucocorticoid-induced tumor necrosis factor receptor-related protein; HMGB1, high mobility group box 1; ICAM-1, intercellular adhesion molecule 1; iNOS, inducible nitric oxide synthase; IL, interleukin; INOS, inducible nitric oxide synthase; KITL (also known as KITLG and SCF), stem cell factor; LOX, lysyl oxidase; MMP, matrix metalloproteinase; NET, neutrophil extracellular

of metastasis

and Karin E. de Visser




2




5 Extravasation

For extravasation, cancer cells need to arrest at a metastatic site, adhere to the endothelium and modulate it to migrate through and invade the surrounding tissue. Immune cells can aid cancer cells in this process.




6 Colonization and persistent growth


The establishment of a supportive immunosuppressive (pre-)metastatic niche favors metastatic colonization, and it remains equally important during persistent growth. Whether we can truly distinguish the pre-metastatic niche from the metastatic niche is a matter of debate.



Common sites of metastasis



Cell key



trap; PD-1, programmed death 1; PD-L1, programmed death ligand 1; PGE₂, prostaglandin E₂; PGF, placental growth factor; RANKL, receptor activator of nuclear factor kappa-B ligand; ROS, reactive oxygen species; S100A, S100 calcium-binding protein A; SAA3, serum amyloid A3; Sema3A, semaphorin 3A; TCR, T cell receptor; TGFβ, transforming growth factor β; TLR4, toll-like receptor 4; TME, tumor microenvironment; TNFα, tumor necrosis factor α; TSP1, thrombospondin 1; VCAM1, vascular cell adhesion protein 1; VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor; VLA4, very late antigen-4

draining lymph nodes and present tumor-derived antigens on MHC-I or MHC-II (see **Glossary, Box 1**) molecules to T cells. If T cells are, in turn, properly activated by DCs, they migrate to the tumor tissue and, upon recognition of their target antigen, induce cancer cell killing.

The spontaneous induction of effective anti-tumor immune responses that protect individuals from non-viral-induced tumors have been a matter of controversy^{6,7}. However, in the 1990s, several important pre-clinical and clinical observations supported the theory that the immune system controls some tumors. For instance, mice lacking T and B cells⁸ or perforin-1 (**Box 1**)^{9,10} display a higher incidence and accelerated growth of immunogenic, chemically induced tumors. Moreover, the seminal work of Boon and colleagues, who identified tumor-specific antigens and T cells with specificity against these antigens in patients, proved that the adaptive immune system can detect cancer cells¹¹. The immune system's capacity to impair tumor growth is further supported by correlative studies showing a direct association between intratumoral infiltration of T cells and patient survival across different cancer types, including – but not limited to – ovarian, breast and colorectal cancer¹²⁻¹⁴.

Clinical and experimental observations support the concept that the adaptive immune system may also protect against metastatic lesions. For instance, the depletion of CD8⁺ T cells in a spontaneous melanoma mouse model increased the formation of lung and reproductive tract metastases, demonstrating the anti-metastatic potential of T cells^{15,16}. Besides T cells, natural killer (NK) and other immune cells may exert anti-metastatic functions¹⁷. Indeed, pre-clinical studies report that defects in the NK cell compartment increase the risk of metastatic disease in mice^{9,18-20}. Moreover, an inverse correlation between the number of circulating or tumor-infiltrating NK cells and the presence of metastasis has been observed in patients with various solid tumors, such as colorectal and gastric cancer^{21,22}. Macrophages, neutrophils, eosinophils, and mast cells can also mediate cancer cell killing directly through phagocytosis, production of reactive oxygen species, and secretion of cytokines, or indirectly by mediating the recruitment of T cells into the tumor through chemokine production²³⁻²⁷. However, as we discuss below, most studies on these myeloid immune cells point towards pro-metastatic functions.

In conclusion, the immune system can evoke an effective anti-tumor response (see **poster, 'Anti-tumor immunity'**), but the sole presence of anti-tumor T cells or high NK cell numbers in cancer patients do not guarantee protective immunity, and the cancer-immunity cycle is frequently hampered in cancer patients. In the next sections, we discuss the mechanisms by which tumors escape from immune control.

Tumor-promoting inflammation

One mechanism of immune evasion by tumors is the establishment of an immunosuppressive environment that inhibits the development or the efficacy of anti-tumor immune responses, both locally and systemically (see **poster, 'Immunosuppression'**). Importantly, depending on the tumor type and stage, various immune cell populations contribute to the immunosuppressive environment. Immune cells exhibit considerable diversity and plasticity, and they respond to environmental signals by acquiring distinct functional phenotypes that can

either inhibit or promote metastasis. Indeed, cancer cell-derived cytokines, such as transforming growth factor β (TGF β) and interleukin (IL)-10 (**Box 1**), frequently skew the differentiation of tumor-infiltrating immune cells into a tumor-promoting phenotype²⁸⁻³². These tumor-educated myeloid cells, particularly tumor-associated macrophages (TAMs) and neutrophils (TANs), can inhibit anti-tumor immune responses through the production of immunosuppressive cytokines, the expression of T cell co-inhibitory molecules, the consumption of amino acids that are crucial for the activity of effector T cells, and the production of reactive oxygen species³³. Indeed, across almost all solid tumor types, a high neutrophil-to-lymphocyte ratio in the circulation is associated with poor survival³⁴. Likewise, TAM abundance correlates with poor clinical outcome in several types of cancer^{35,36}.

The acquired phenotype of tumor-educated immune cells differs depending on cancer type and stage. For instance, neutrophils evolve from cytotoxic into tumor-promoting cells during tumor progression in mice bearing transplantable lung and mesothelial tumors³⁷. This observation is in line with clinical data showing that neutrophils isolated from surgically resected early-stage lung cancers were anti-tumorigenic and able to stimulate T cell proliferation and interferon- γ (IFN γ ; **Box 1**) release³⁸. However, the bulk of experimental and clinical evidence supports the notion that neutrophils in advanced cancers sustain cancer progression and metastasis^{34,39,40}.

In addition to shaping immune cell functions, tumor-derived factors critically stimulate the recruitment and expansion of myeloid cells (see **poster, 'Recruitment of pro-tumorigenic immune cells'**). Aberrant cytokine and chemokine production in the primary tumor drives the mobilization and recruitment of myeloid cells by manipulating their generation and release from the bone marrow⁴¹⁻⁴⁴. Hematopoietic stem and progenitor cells are frequently observed in the circulation of cancer patients compared with healthy controls, and these progenitors exhibit a myeloid bias toward granulocytic differentiation⁴⁵. This tumor-induced skewing of hematopoiesis and the systemic accumulation of myeloid cells has consequences for the immune composition of the TME and (pre-)metastatic organs. Indeed, TAMs are abundant in the TME of many cancer types³⁹, and the circulation of cancer patients frequently contains expanded neutrophil populations³⁴.

The aberrant cytokine production driving immune recruitment and polarization occurs by cancer cells directly, or through increased cytokine expression in the TME by, for instance, fibroblasts^{46,47} and immune cells. Our group previously reported that TAMs in a spontaneous model of breast cancer produce IL-1 β , which stimulates the expression of IL-17 (also known as IL-17A) from $\gamma\delta$ T cells (**Box 1**). In turn, IL-17 induces granulocyte-colony stimulating factor (G-CSF, also known as CSF-3; **Box 1**) expression, which drives systemic neutrophil accumulation. These neutrophils acquire an immunosuppressive phenotype and promote metastasis by suppressing CD8⁺ T cells⁴⁴. Furthermore, in a spontaneous mouse model of mammary tumorigenesis, intratumoral CD4⁺ T cells produced cytokines, such as IL-4 and IL-13, which favor the activation and polarization of tumor-promoting immune cells, such as TAMs⁴⁸.

Besides neutrophils and macrophages, other immune cells are implicated in tumor-promoting inflammation. DCs, which are required for the development of

anti-tumor immune responses, can exert opposing functions and contribute to the generation of an immunosuppressive TME⁴⁹. The context in which DCs encounter antigens dictates their ability to trigger either immunity or tolerance³⁰. Tumor-derived factors interfere with the maturation of DCs, inducing a tolerogenic or immature phenotype characterized by low expression of co-stimulatory molecules and altered cytokine production both in patients and in mouse models⁵⁰⁻⁵³. Tolerogenic DCs inhibit anti-tumor T cell responses by impairing tumor antigen presentation, stimulating T cell exhaustion and inducing regulatory T cells (T_{regs})^{53,54}. Depending on the cancer type, T_{regs} can make up a substantial proportion of tumor-infiltrating lymphocytes³⁹. Although their immunosuppressive activity is crucial for preventing autoimmunity and excessive responses to pathogens, accumulation of T_{regs} and, in particular, a high ratio of T_{regs} versus effector T cells in tumor tissue, is associated with worse clinical outcome in the majority of solid tumors⁵⁵. Regulatory B cells (B_{regs}), a subpopulation of B cells with immunosuppressive functions, also contribute to tumor immune escape⁵⁶. A key function of B_{regs} is the conversion of CD4⁺ T cells into T_{regs} via IL-10 and TGFβ secretion^{57,58}. Indeed, B_{reg}-deficiency reduced metastasis formation via loss of T_{reg} cell conversion in transplantable breast cancer models⁵⁷. Other pre-clinical studies have described B_{regs} as essential for myeloid cell polarization towards immunosuppressive phenotypes and subsequent metastasis formation⁵⁹. More recently, B_{reg} expression of PD-L1 (also known as CD274) has been recognized as an important mediator of their immunosuppressive function, both in mouse models and invasive breast cancer patients^{60,61}. Lastly, B cell-derived antibodies forming circulating immune complexes can promote cancer development by engaging activating Fcγ receptors on myeloid cells, which in turn regulate immune cell recruitment and function in the TME of human papilloma virus (HPV)-driven murine skin cancer lesions⁶². Whether immune complexes also play a role in metastasis is largely unknown.

In summary, the inhibition of the anti-tumor immune response through the orchestration of an immunosuppressive microenvironment is a crucial mechanism that contributes to cancer progression and metastasis. Importantly, tumor-educated immune cells can promote metastasis by additional means that go beyond the suppression of anti-tumor immunity. In the next sections, we address some of these mechanisms, and discuss how they may affect the metastatic cascade.

Immune regulation of cancer cell invasion and intravasation

In order to metastasize, cancer cells need to egress from the primary site, invade the surrounding tissue and intravasate into blood or lymphatic vessels (see **poster, panels 1 and 2, 'Primary tumor growth' and 'Local invasion and intravasation'**). Immune cells modulate these initial steps of the metastatic cascade by influencing extracellular matrix (ECM; **Box 1**) organization, vessel formation and permeability, and the motility of cancer cells. Different immune-mediated mechanisms are likely active or dominant in different tumor settings.

Immune cells are important regulators of the ECM, which affects many aspects of tumor biology⁶³. ECM remodeling can promote metastasis by different mechanisms: for instance, altered ECM dynamics favor tumor cell invasion by critically influencing the architecture of the surrounding tissue⁶⁴, or by allowing

the release and diffusion of growth factors and other pro-tumoral signaling molecules that are normally sequestered by the ECM⁶⁵. Various tumor-associated immune cells, but also fibroblasts and endothelial cells, influence the composition, organization and dynamics of the ECM by secreting ECM remodeling enzymes, such as matrix metalloproteinases (MMPs), cathepsins and other proteases. TAMs, TANs and mast cells (**Box 1**) can directly secrete ECM remodeling proteases⁶⁶⁻⁶⁸, and B_{regs} can induce MMP expression in cancer cells⁶⁹. In mouse models of lung and skin cancer, immune cells are the main source of pro-tumorigenic and pro-metastatic MMPs^{70,71}. Noteworthy, the capacity of immune cells to remodel the ECM may also be beneficial for the development of an effective immune response: for instance, recent work in mice showed that the expression of specific ECM-remodeling enzymes in NK cells is crucial for their infiltration in lung metastatic lesions, and critically promoted immune control of the tumor⁷².

Immune cells are also important regulators of angiogenesis and lymphangiogenesis^{73,74}. TAMs, mast cells and T_{regs} have been positively associated with blood vessel number or density in different types of tumors, including melanoma, pancreatic, breast and gastric cancer⁷⁵⁻⁷⁸. Blood and lymphatic vessels are essential for metastatic spread because they represent the main routes for cancer cell migration to distant sites⁷⁹. Additionally, blood vessels are a key supplier of nutrients and growth factors for the tumor. A dysfunctional vasculature, often the result of tumor-induced angiogenesis, is more permissive to tumor cell intravasation⁸⁰. It also affects the infiltration of immune cells in the TME, potentially preventing the action of the anti-tumor immune response⁸¹. A major promoter of angiogenesis in the TME is hypoxia, caused by uncontrolled cell proliferation and concomitant lack of sufficient oxygen supply⁸². Hypoxia, in turn, influences the recruitment and function of tumor-infiltrating immune cells, promoting their pro-angiogenic functions⁸³. For instance, TAMs can react to hypoxia by producing pro-angiogenic and lymphangiogenic factors, most importantly vascular endothelial growth factor A (VEGFA), which stimulates the proliferation and migration of endothelial cells⁸⁴. Other tumor-infiltrating immune cells, such as T_{regs} and mast cells, can also produce VEGFA^{85,86}. Moreover, CD4⁺ T cell-derived cytokines, such as IL-17, can promote the direct expression of VEGF in human cancer cells⁸⁷, and TAM- and TAN-derived ECM remodeling enzymes, such as MMP9, can induce the release of pro-angiogenic factors that are trapped in the ECM⁸⁸. Interestingly, Tian and colleagues recently used transplantable mouse mammary tumor models and patient xenografts to show that intratumoral conventional CD4⁺ T cells contribute to vessel normalization, and that the vascular normalization gene expression signature correlated with T cell infiltration and activation in human breast and liver cancers⁸⁹. These results, which are in contrast to the pro-angiogenic role of CD4⁺ T cells, suggest that CD4⁺ T cells can potentially decrease tumor cell intravasation through a mechanism independent of the direct immune-mediated elimination of cancer cells.

Lastly, immune cells can directly promote tumor cell migration. For instance, work in a spontaneous mammary tumor model showed that IL-4/IL-13-activated TAMs, when exposed to tumor-derived colony-stimulating factor-1 (CSF-1; **Box 1**), produce epidermal growth factor (EGF), which in turn promotes motility

and intravasation of EGF receptor (EGFR)-expressing tumor cells⁹⁰. Noteworthy, intratumoral CD4⁺ T cells play a key role in this process, promoting the pro-metastatic TAM phenotype through IL-4 and IL-13 production⁴⁸, which further highlights the dual role of CD4⁺ T cells in the early dissemination of cancer cells. Collectively, these data indicate how the intratumoral immune infiltrate strongly influences invasion and intravasation of cancer cells through a plethora of different mechanisms.

Immune regulation of circulating tumor cell survival and extravasation

After intravasation, cancer cells need to survive in circulation, until they extravasate and colonize a distant site (see **poster, panel 3, 'Survival in circulation'**). Circulating tumor cells (CTCs) endure a hostile environment, withstanding the shear stress of blood flow, death by anoikis (**Box 1**) and immune system attacks. A decreased cytotoxic functionality of NK cells correlates with increased numbers of CTCs in patients with metastatic breast, colorectal and prostate cancer^{91,92}, and liver-resident macrophages play a key role in trapping and eliminating CTCs⁹³, especially in the context of tumor-targeting antibody therapies⁹⁴. Furthermore, in patients with lung and breast cancer, the number of CTCs inversely correlates with the percentage of circulating T cells^{95,96}. However, the immune system can also promote CTC survival. For instance, CTCs directly interact and associate with platelets, which promotes their activation⁹⁷. Consequently, activated platelets form a fibrin clot around CTCs, which promotes CTC survival by shielding them from NK cell attack⁹⁸. Moreover, T_{regs} can directly provide survival signals to CTCs through the production of receptor activator of nuclear factor- κ B ligand (RANKL)⁹⁹. CTCs can employ additional strategies to escape immune control. For instance, CTCs in colorectal cancer patients were shown to upregulate the anti-phagocytic molecule CD47 (**Box 1**), compared with matched primary tumors¹⁰⁰. Moreover, researchers observed increased levels of secreted HLA-G (**Box 1**) in the blood of breast cancer patients compared with healthy controls, and that the number of CTCs in patients directly correlates with the level of secreted HLA-G¹⁰¹. This suggests that HLA-G-induced immunosuppression mechanisms are important for the survival of CTCs. Finally, the presence of CTCs in breast cancer patients associates with an increased percentage of FAS-expressing T cells. Upon triggering by its ligand, FASL, FAS induces T cell apoptosis¹⁰². Noteworthy, the aforementioned immune escape strategies used by CTCs provide circumstantial evidence for the role of NK and T cells in eliminating CTCs; further work is needed to provide insights on the mechanisms used by these immune cells to eliminate CTCs from the flowing blood.

Although CTCs employ several strategies to survive the hostile environment of the circulation, their metastatic potential eventually depends on their ability to extravasate and grow out in distant organs (see **poster, panel 5, 'Extravasation'**). For extravasation, cancer cells need to adhere to the endothelium and modulate it so they can migrate through and invade into the surrounding tissue at a distant site. Tumor cells can be physically restrained in small capillaries, but extravasation from larger vessels requires active adhesion processes that immune cells can contribute to. For instance, neutrophils release neutrophil extracellular traps (NETs; **Box 1**) that trap CTCs in distant organs and stimulate their invasion and expansion^{103,104}. The

interaction of neutrophil integrin CD11b (also known as ITGAM) with intercellular adhesion molecule 1 (ICAM-1; **Box 1**) on cancer cells¹⁰⁵ and platelet-induced clot formation¹⁰⁶ further promote tumor cell adhesion. Platelets also contribute to extravasation by promoting an invasive mesenchymal-like phenotype in cancer cells through direct platelet-cancer cell interactions and through the release of TGFβ¹⁰⁷, or by releasing ATP-containing granules that modulate the endothelial lining and cause vascular leakiness¹⁰⁸.

In addition to neutrophils and platelets, recruitment of monocytes to extravasation sites enhances cancer cell survival and extravasation. *Ex vivo* imaging studies in experimental lung metastasis models have demonstrated that inflammatory monocytes aid extravasation by physically associating with cancer cells as they migrate through the endothelial lining¹⁰⁹. Additionally, inflammatory monocytes promote vascular permeability and subsequent metastatic seeding through VEGF production in an orthotopic breast cancer model¹¹⁰. These inflammatory monocytes differentiate into immunosuppressive precursors of metastasis-associated macrophages that suppress CD8⁺ T cells upon recruitment into metastatic sites in mouse models of breast cancer¹¹¹.

Although the studies described above were conducted in different models of metastasis and identify distinct mechanisms, it is likely that various cells work together to promote extravasation and survival. Indeed, some studies have reported crosstalk between platelets, endothelial cells, and macrophages, as well as neutrophils¹¹². Thus, although the immune system contributes to the clearing of CTCs, it can also promote their survival and mediate their extravasation. Once more, the balance between pro-tumoral inflammation and anti-tumor immunity crucially determines the outcome of these steps of the metastatic cascade.

The (pre-)metastatic niche; immune cells as key coordinators of 'fertile soil'

The processes that regulate and determine the sites where metastases will form have been debated for decades. In 1889, Stephen Paget proposed the 'seed and soil' hypothesis, which postulates that the distribution of metastases is not random; instead, cancer cells (the 'seeds') colonize preferentially those organs in which the environment is favorable (the 'congenial soil')¹¹³. Paget's view was challenged in the late 1920s by James Ewing, who argued that organotropism could be explained solely by the design of the circulatory system¹¹⁴. This remained the dominant view until the 1970s, when Isaiah Fidler provided the first experimental evidence to support Paget's hypothesis by demonstrating that, although the design of the circulatory system is important, certain cancer types only colonize particular organs¹¹⁵. In the following years, studies addressing the determinants of organotropism focused mostly on tumor-intrinsic properties. For instance, human breast cancer cells frequently express the chemokine receptors CXCR4 and CCR7, which have been reported to guide their spread to the bone, lung and regional lymph nodes that express high levels of the ligands CXCL12 and CCL21, respectively¹¹⁶. It became apparent in recent years that factors extrinsic to the tumor, in particular stromal and immune cell populations, are equally important determinants for metastatic spread. Tumors actually prepare distant organs for the arrival of disseminated cancer cells by inducing a number of systemic molecular and cellular changes that create a

supportive and receptive microenvironment for colonization, referred to as the pre-metastatic niche (see **poster, panel 4, 'The (pre-)metastatic niche'**).

In a pioneering paper that emphasized the significance of immune cells in the formation of the (pre-)metastatic niche, Kaplan and colleagues demonstrated that VEGF receptor 1-expressing (VEGFR1⁺, also known as FLT1) bone marrow-derived cells (BMDCs) are recruited to the lung in response to tumor-derived VEGFA and placental growth factor before the arrival of transplanted tumor cells¹¹⁷. The BMDCs established a permissive niche for incoming tumor cells through expression of chemoattractants. This was the first study to demonstrate how immune cells orchestrate the site of future metastases. Later studies shed more light on how an intimate crosstalk between primary tumor-derived factors, the local stromal microenvironment and BMDCs regulates the formation of the (pre-)metastatic niche¹¹⁸. As the primary tumor grows and becomes more hypoxic and inflammatory, increased secretion of tumor-derived factors^{118,119} and extracellular vesicles^{120,121} stimulates the mobilization and recruitment of (immature) myeloid cells directly from the bone marrow, thereby initiating the (pre-)metastatic niche. These factors also induce changes in the stromal compartment of the distant organ that support the influx of BMDCs and CTCs^{122,123}. Continuous influx of BMDCs further remodels the local environment into a tumor-promoting (pre-)metastatic niche characterized by increased angiogenesis and vascular permeability, ECM remodeling, chronic inflammation and immunosuppression¹¹⁸.

Neutrophils, macrophages and fibroblasts have been identified as the main sources of proangiogenic molecules like Bv8 (also known as PROK2), as well as of ECM remodeling factors, such as fibronectin and lysyl oxidase (LOX). These facilitate tumor cell recruitment and extravasation in the (pre-)metastatic niche^{42,110,122,124,125}. Chronic inflammation in the (pre-)metastatic niche is an important driver of metastasis by promoting the recruitment of both BMDCs and tumor cells to distant organs^{126,127}. For instance, blocking pro-inflammatory molecules or their receptors suppressed the recruitment of myeloid cells to the pre-metastatic niche and, in turn, hampered metastasis formation in Lewis lung carcinoma and B16 melanoma models^{123,128}. Lastly, the establishment of an immunosuppressive microenvironment is an essential characteristic of the (pre-)metastatic niche. It allows cancer cells to escape immune recognition and progress to form macro-metastases^{129,130}. Our group and others have shown that tumors induce systemic accumulation of immunosuppressive neutrophils that promote metastasis by suppressing CD8⁺ T cell responses^{44,131}, highlighting immunosuppression as an essential feature of metastasis formation.

Although it is clear that establishment of a supportive immunosuppressive environment greatly favors metastatic seeding (see **poster, panel 6, 'Colonization and persistent growth'**), whether we can truly distinguish the pre-metastatic niche from the metastatic niche is debatable, because providing evidence of the absence of cancer cells in the (pre-)metastatic niche is challenging. Moreover, many of the changes induced by growing tumors are systemic in nature, not limited to organs in which metastases will develop. Some elements of the (pre-)metastatic niche that have been described in mice can be found in clinical samples. These include neutrophil accumulation in the blood³⁴, clusters of VEGFR1⁺ cells detected

in common sites of metastasis before tumor spread¹¹⁷, elevated MMP9 levels in the lungs of patients with distant tumors¹²⁴, and LOX and CD11b⁺ cells in metastatic tissues¹²². Although this evidence is indirect, from a clinical perspective, it would be very interesting to identify biomarkers that could identify cancer patients with signs of pre-metastatic niche formation, and to treat these patients with pre-metastatic niche-disrupting agents.

Inhibiting tumor promoting inflammation to fight metastatic disease

Inhibiting tumor-promoting inflammation is an appealing strategy to fight metastasis. Given the clear immunosuppressive and pro-metastatic roles of tumor-infiltrating macrophages, neutrophils, and T_{regs}, researchers are extensively exploring strategies targeting their recruitment, polarization, and effector molecules (see **poster, 'Recruitment of pro-tumorigenic immune cells'**). Noteworthy, the effects of targeting pro-tumor immune cells can go beyond the activation of anti-tumor immune responses. For instance, depletion/repolarization of TAMs might affect their pro-angiogenic and ECM remodeling functions as well as their immunosuppressive functions¹³². Although this line of research is relatively new, the oncology field can adopt the cytokine and receptor inhibitors that are FDA approved for the treatment of chronic inflammatory and autoimmune diseases.

Receptors that mediate the recruitment of pro-metastatic immune cells and their respective ligands are potentially important targets for the treatment of metastasis. Among these, perhaps the most explored approach to date is targeting the CSF-1/CSF-1R pathway that mediates macrophage infiltration¹³³. In a mouse model of spontaneous breast cancer, researchers showed that genetic ablation of CSF-1 does not affect primary tumor incidence or growth, but strongly inhibits the development of metastases through a reduction in TAMs¹³⁴. Therapeutic targeting of this axis inhibited metastasis formation in mouse models of breast and pancreatic cancer^{135,136}. Preliminary results of a clinical trial with a monoclonal antibody against CSF-1R showed a reduction in TAMs and an increase in CD8⁺/CD4⁺ T cell ratio in patients with various solid tumors and led to good objective responses in diffuse-type giant cell tumor patients (Dt-GCT; **Box 1**)¹³³. This provided the first evidence for the clinical benefit of CSF-1/CSF-1R pathway targeting for the treatment of cancer.

Similarly, disruption of neutrophil recruitment through CXCR2 blockade prevented metastasis formation in cell line, xenograft and spontaneous models of rhabdomyosarcoma, colon and pancreatic cancer^{126,137,138}, and several CXCR2 inhibitors are currently under clinical investigation. The dominant pathway for T_{reg} recruitment is through tumor- or TAM-derived CCL22 that binds CCR4 on T_{regs}, providing rationale for CCR4 antagonists¹³⁹⁻¹⁴¹.

The upstream soluble mediators that drive pro-metastatic immune cell expansion and accumulation could also be potential targets. A candidate signaling pathway to prevent neutrophil accumulation is the IL-1 β -IL-17-G-CSF axis⁴⁴. T_{regs} expand in response to TGF β or elevated levels of prostaglandin E2 (PGE2; **Box 1**)^{57,142}, arguing for TGF β neutralization or inhibitors of cyclo-oxygenases (COX; **Box 1**) as potential targets¹⁴³. Moreover, stromal fibroblast-derived TGF β is an important driver of immune evasion and metastasis and conveys resistance to PD-L1 blockade in a mouse model of spontaneous colon cancer metastasis and in metastatic

urothelial cancer patients^{47,144}.

The CCL2/CCR2 interaction could be an attractive target to prevent monocyte recruitment, but clinical trial results have been inconsistent^{145,146}. CCL2 neutralization inhibited metastasis formation by retaining monocytes in the bone marrow in spontaneous breast and pancreatic cancer models of metastasis^{110,135}, but cessation of treatment caused a compensatory influx of monocytes into metastatic sites and resulted in increased mortality¹⁴⁷. Relatedly, depending on the tumor characteristics, treatment with single chemokine/receptor antagonists might not be sufficient to suppress metastasis formation, as ligand and receptor redundancy allows recruitment of specific cell types^{40,145}. Moreover, several immune cell types may support metastasis formation – targeting one could lead to a compensatory increase and dependency on the other. Indeed, inhibition of TAMs through CSF-1R targeting led to neutrophil accumulation and enhanced metastasis formation in transplantable mouse models of melanoma, lung, colon and breast cancer^{148,149}. In the Lewis lung carcinoma model of spontaneous metastasis, CSF-1R inhibition unexpectedly promoted metastasis formation by indirectly diminishing NK cell numbers through removal of the TAM-derived NK cell survival signal IL-15¹⁵⁰. These studies emphasize the complexity of targeting the dynamic cancer-immune cell interactions, especially with the myeloid compartment.

Instead of inhibiting the recruitment of specific immune cells, repolarizing immune cells from a pro-tumorigenic to anti-tumorigenic phenotype might be a preferred strategy. For instance, TAMs could be re-educated into an anti-tumor phenotype by CSF-1R inhibition or by pattern recognition receptor (PRR; **Box 1**) ligands, which inhibited tumor growth in a mouse model of glioblastoma multiforme¹⁵¹ and lung cancer¹⁵², respectively. Similarly, TGF β blockade reverted immunosuppressive neutrophils into a cytotoxic phenotype²⁹. Re-programming of the immunosuppressive microenvironment might also be achieved through signal transducer and activator of transcription 3 (STAT3; **Box 1**) inhibition^{153,154}. T_{regs} might be targeted by glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR; **Box 1**) agonists, which were shown to convert T_{regs} into anti-tumor effector T cells that have lost immunosuppressive functions in a melanoma model¹⁵⁵. Whether these changes in immune cell phenotype affect metastasis formation requires further investigation.

Finally, targeting the immunosuppressive mediators and cytokines in the TME has shown promise as well. Neutralization of TAM-derived IL-10 enhanced T cell responses to a similar extent as TAM depletion using anti-CSF-1 antibodies in a spontaneous breast cancer mouse model¹³⁶.

Because the availability of drugs that specifically target pro-tumor immune cells is still limited, an alternative approach is to use conventional anti-cancer therapies with immunomodulatory properties, such as chemotherapy, radiotherapy and oncogene-targeted therapies^{156,157}. These approaches can directly deplete certain pro-tumor immune populations^{158,159}, or indirectly activate anti-tumor immune response through increased antigen availability and induction of immunogenic cell death¹⁶⁰.

Although the different strategies discussed in this section might be effective in alleviating pro-tumor inflammation, it is likely necessary to combine

strategies targeting the immunosuppressive TME with therapies aimed at boosting the anti-tumor immune response (**Box 2**), in order to maximize therapeutic benefit. A growing body of pre-clinical evidence supports this approach. For instance, CXCR2 blockade improved the response to checkpoint blockade in transplantable rhabdomyosarcoma and spontaneous pancreatic cancer models^{137,138}. Furthermore, CSF-1R inhibition enhanced the efficacy of adoptive T cell transfer in transplantable melanoma models¹⁶¹. Although some of the aforementioned strategies still await verification in the clinical setting, several approaches are currently in early clinical trials evaluating their safety and tolerability, and measurements of secondary outcomes including tumor-infiltrating immune cells or cytokine and chemokine serum levels will provide the first indication of the therapeutic value of these approaches.

Conclusion and perspective

The recent achievements of immunotherapy for the treatment of advanced metastatic cancers (**Box 2**) have encouraged many clinical trials assessing the efficacy of these approaches in different tumor types, alone and in combination with conventional therapies. Notwithstanding the clinical successes of cancer immunotherapy, clinical trials are currently outpacing our scientific understanding of the immune-related mechanisms that influence metastasis formation and response to therapy. Several challenges remain. Tumors of different types, and even individual tumors of the same type, vary greatly in their immune landscape, both locally and systemically³⁹, and the reasons behind this heterogeneity are still largely unexplained. Moreover, the different factors that regulate the sensitivity of organ-specific metastases versus primary tumors to immunomodulation are unknown. For instance, differences in metabolism, genetic makeup or epigenetics between cancer cells in the primary tumors versus metastases are likely to contribute to their differential sensitivity to immunotherapy. A fundamental understanding of these unresolved issues is essential to make rational decisions about which patients to select, to tackle therapy resistance and design the most optimal therapy combinations, and thus maximize the therapeutic benefit of immunomodulatory strategies. The use of spontaneous mouse tumor models that closely recapitulate the different metastatic steps, and in-depth characterization of the immune landscape in those models, in combination with comprehensive immune monitoring in cancer patients will be critical to rationally design the most efficacious immunotherapy strategies to tackle metastases in individual patients, striving towards personalized immune interventions.

Box 1. Glossary

$\gamma\delta$ T cells: 'unconventional' T cell subset that recognizes target antigens in a MHC-independent manner and expresses T cell receptors (TCRs) composed of γ and δ chains, as opposed to conventional helper and cytotoxic T cells, which express $\alpha\beta$ TCRs.

Anoikis: programmed cell death induced by the loss of anchorage with the extracellular matrix.

Colony-stimulating factor-1 (CSF-1): also known as macrophage colony-stimulating factor-1, a cytokine that controls macrophage and monocyte lineage development, differentiation, survival and migration.

Cyclo-oxygenases (COX): enzymes that catalyze the synthesis of prostaglandins, which play crucial roles in the development of inflammation. COX1/2 enzymes are the target of nonsteroidal anti-inflammatory drugs (NSAIDs), such as aspirin.

CD47: transmembrane protein of the immunoglobulin family that is expressed on all the cells of the body. CD47 regulates various cellular functions, such as cell migration and cytokine production, but it is mainly known for its anti-phagocytic function and its function as a 'don't eat me' signal. Through the binding of SIRP α on myeloid cells, CD47 inhibits the phagocytosis of CD47-expressing cells. CD47 is frequently overexpressed by cancer cells of multiple tumor types.

Diffuse-type giant cell tumor (Dt-GCT): A rare proliferative disease affecting the joints that is characterized by CSF-1 overexpression. In the majority of Dt-GCT patients, CSF-1 overexpression is the result of a chromosomal translocation involving the gene encoding for CSF-1. This leads to massive recruitment of CSF-1R $^{+}$ cells such as macrophages.

Extracellular matrix (ECM): an extracellular network of macromolecules including collagen, fibronectin and proteoglycans that regulates many aspects of cell behavior, such as cell-to-cell communication, cell adhesion, development and migration, both in healthy and in tumor tissue. The ECM is a highly dynamic structure that can be remodeled by proteases, such as MMPs and cathepsins. Tumors often overexpress ECM remodeling enzymes and altered ECM dynamic contribute to cancer progression.

Glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR): immune checkpoint molecule, expressed on effector and regulatory T cells, which plays a role in immunological self-tolerance.

Granulocyte-colony stimulating factor (G-CSF): a cytokine that regulates granulocyte development, differentiation, and recruitment.

HLA-G: a non-classical MHC-I molecule with multiple immunosuppressive functions, such as the ability to induce apoptosis and inhibit the cytotoxic activity of T and NK cells¹⁶².

Intercellular adhesion molecule 1 (ICAM1): cell adhesion protein, expressed on endothelial and immune cells, that is involved in cell-cell interactions and leukocyte endothelial transmigration into tissues. ICAM1 binds to several integrins including

CD11b.

Interferon- γ (IFN γ): a pro-inflammatory cytokine of the type II class of interferons with anti-viral and anti-tumor activities. It is produced mainly by NK and T cells.

Interleukins (ILs): cytokines or immunomodulatory mediators that can have pro- and anti-inflammatory functions.

Major histocompatibility complex I and II (MHC-I and MHC-II): a class of proteins that binds and presents peptides on the cell surface for recognition by T cells. MHC-I is expressed by all nucleated cells and presents peptides to CD8⁺ cytotoxic T cells. The downregulation of MHC-I expression by cancer cells is a frequent mechanism of tumor escape from T cell immune recognition. MHC-II is expressed by professional antigen-presenting cells, such as dendritic cells, macrophages and B cells, and presents peptides to CD4⁺ T cells. MHC molecules are fundamental for the development of adaptive immunity.

Mast cells: innate immune cells that store cytokines, chemokines, proteases and pro-angiogenic factors in large cytoplasmic granules. Mast cells are one of the main producers of histamine and play a crucial role in allergic responses, parasitic and bacterial infections and in cancer.

Neutrophil extracellular trap (NET): extracellular neutrophil-derived network of expelled DNA, fibers, histones and proteolytic enzymes. Release of NETs (NETosis) occurs in cases of pathogen infection, sterile inflammation and cancer.

Pattern recognition receptor (PRR): receptor that recognizes common pathogen-derived molecules and cell-derived danger signals called pathogen- and damage-associated molecular patterns, respectively. They play a role in activation of the innate immune system.

Perforin: glycoprotein produced mainly by cytotoxic T cells and NK cells. Upon release, perforin forms pores in the cell membrane of target cells and ultimately induces their lysis.

Prostaglandin E2 (PGE2): a bioactive lipid with a wide range of functions in inflammation and cancer. It is one of the downstream products of arachidonic acid metabolism by COX.

Signal transducer and activator of transcription 3 (STAT3): a transcriptional regulator expressed by many cell types including cancer and myeloid cells that promotes cell survival, proliferation and the secretion of pro-inflammatory factors. STAT3 activation in myeloid cells controls myeloid cell differentiation and recruitment as well as the production of immunosuppressive mediators, such as inducible nitric oxide synthase (iNOS), arginase 1 (Arg-1) and indoleamine-pyrrole 2,3-dioxygenase (IDO).

Transforming growth factor β (TGF β): a cytokine that plays a dual role in cancer as it has both pro- and anti-inflammatory activities. TGF β can function as a tumor growth suppressor, but it can also enhance tumor cell invasion and inhibit the function of immune cells. In cancer patients, TGF β overproduction is frequently associated with metastasis and poor prognosis.

Box 2. Boosting anti-tumor immunity to fight metastatic disease

The immune system is tightly intertwined with the metastatic cascade, and the balance between pro-tumor inflammation and anti-tumor immunity is a key factor in metastasis. Shifting the balance towards anti-tumor immunity therefore represents an attractive therapeutic approach to prevent or cure metastasis (see **poster, 'Anti-tumor immunity'**).

A promising strategy to boost anti-tumor immune responses is the use of immune checkpoint inhibitors, which target T cell-inhibitory molecules, such as PD-1 and CTLA-4. Although the exact mechanism is still debated, blocking PD-1 (or its ligand PD-L1) and CTLA-4 improved the survival of patients with advanced metastatic melanoma and with other solid tumors to an extent that no other therapeutic strategy, including non-immune based approaches, ever reached¹⁶³⁻¹⁶⁵. The striking clinical efficacy of immune checkpoint inhibitors for advanced metastatic cancers represented a crucial breakthrough and fueled the acknowledgment of immunotherapy as one of the pillars of cancer therapy. In addition to metastatic melanoma, antibodies targeting inhibitory or immune checkpoint molecules are now FDA approved for the treatment of metastatic non-small cell lung cancer, renal cell carcinoma, and head and neck squamous cell carcinoma, and for all metastatic solid tumor types with high microsatellite instability or DNA mismatch repair deficiency¹⁶⁶. That said, only a proportion of patients respond to immune checkpoint inhibitors¹⁶⁷, and the efficacy of this approach against other – less immunogenic – metastatic cancers is expected to be less spectacular and might require combination strategies.

Another approach to exploit the immune system to fight metastatic disease is adoptive cell transfer (ACT) of specific anti-tumor T lymphocytes into patients, after *ex vivo* expansion, activation and, sometimes, genetic modification^{168,169}. The use of autologous T cells that recognize antigens derived from somatic mutations in cancer cells proved effective for the treatment of patients affected by metastatic melanoma, breast, colorectal and bile duct cancers¹⁷⁰⁻¹⁷³. This technology thus represents a promising therapeutic approach for metastatic solid tumors.

An alternative to ACT, which overcomes the hurdle of identifying and isolating tumor-specific T cells for each patient, is to activate endogenous anti-tumor T cells directly *in vivo*. This can be achieved by, for instance, exploiting the central role for DCs in kick-starting anti-tumor immunity. PRR (**Box 1**) ligands can promote the activation and maturation of intratumoral DCs^{174,175}, but their anti-metastatic effect has so far been reported only for skin lesions¹⁷⁶. Alternatively, antibodies that target immuno-stimulatory molecules, such as CD40^{177,178}, can also promote the activation of DCs. However, the benefit of CD40 agonists as monotherapy for the treatment-advanced solid tumors was modest in early-phase clinical trials¹⁷⁹⁻¹⁸¹. A different and tumor-specific DC-based immunotherapy involves the isolation of patient- or donor-derived DCs, or DC precursors, and their maturation and activation *ex vivo*. DCs are then exposed to tumor-derived antigens, such as bulk cancer cell lysate, tumor antigen-derived peptides or mRNAs coding for tumor antigens and re-infused in patients. An example of this approach is Sipuleucel-T, a vaccine formulated to include patient-derived antigen-presenting cells that are activated and exposed to tumor antigens *ex vivo*. Sipuleucel-T was FDA approved in 2010 for the treatment of metastatic castration-resistant prostate cancer¹⁸². In addition, DCs can be targeted

in vivo through vaccination, administrating tumor-derived peptides¹⁸³, or DNA- or mRNA-encoding tumor-derived antigens. Recent work showed that vaccination with RNA coding for neo-antigens of patients with advanced melanoma induced a specific anti-tumor T cell response, promoted the infiltration of neo-antigen-specific T cells in the metastatic lesions and led to objective responses in a significant proportion of the patients¹⁸⁴, illustrating the potential of this approach. Stimulatory cytokines can also promote an anti-tumor T cell response: IL-2, for example, promotes the expansion of T cells, and its administration to metastatic melanoma and renal carcinoma patients produced remarkable clinical benefit¹⁸⁵. However, its use is limited by severe immune-related side effects¹⁸⁶. Currently, researchers are exploring different strategies to reduce IL-2 toxicity – for example, by decreasing its receptor-binding affinity or increasing its half-life, allowing in turn the use of lower doses¹⁸⁷ – but their efficacy and safety in clinical settings remains to be evaluated.

Besides T cells, targeting NK cells represents a promising approach for treatment of metastatic patients. NK cells can be pharmacologically targeted using antibodies that block NK cell inhibitory receptors or trigger activating receptors¹⁸⁸. Moreover, stimulating cytokines such as IL-2 and IL-15 can promote NK cell functionality¹⁸⁹. Finally, NK cells can be adoptively transferred to patients, but so far this has had only limited therapeutic efficacy, despite promising pre-clinical results¹⁹⁰.

Compared with T cells, NK cells and DCs, there have been fewer attempts to directly enhance the anti-tumor activity of myeloid cells such as macrophages and neutrophils, mainly because the majority of myeloid cells have immunosuppressive or pro-tumor functions in the TME. One exception is the use of antibodies targeting CD47, a 'don't eat me' signal often overexpressed on malignant cells¹⁹¹. The antibody binding of CD47 promotes tumor cell phagocytosis by macrophages, neutrophils and DCs¹⁹². The efficacy of this approach is currently under evaluation in clinical trials¹⁹³.

In conclusion, the recent and impressive clinical responses of cancer patients treated with immune checkpoint inhibitors highlight the potential of cancer immunotherapy for the treatment of advanced metastatic disease. However, boosting the immune system might not be enough: considering all immune-boosting strategies described here, their anti-metastatic effect, when applied as monotherapy, is often limited to a proportion of the patients, and to few tumor types. Inhibiting pro-tumoral inflammation represents a promising and complementary strategy to improve the efficacy of immunotherapy for metastatic disease.

Declarations

Acknowledgments

We thank Kevin Kos and Max D. Wellenstein for their valuable comments during the writing process.

Funding

Research in the De Visser laboratory is funded by KWF Kankerbestrijding (KWF10083; KWF10623), the European Research Council (InflaMet 615300), Oncode Institute and the Beug Foundation for Metastasis Research. K.E.d.V. is supported by the EMBO. L.S. is funded by Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (P2FRP3 171794).

References

1. Balkwill, F., and Mantovani, A. (2001). Inflammation and cancer: back to Virchow? *Lancet* 357, 539-545.
2. Coley, W.B. (1991). The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. *Clin Orthop Relat Res*, 3-11.
3. Chittechath, M., Dhillon, M.K., Lim, J.Y., Laoui, D., Shalova, I.N., Teo, Y.L., Chen, J., Kamaraj, R., Raman, L., Lum, J., et al. (2014). Molecular profiling reveals a tumor-promoting phenotype of monocytes and macrophages in human cancer progression. *Immunity* 41, 815-829.
4. Pages, F., Berger, A., Camus, M., Sanchez-Cabo, F., Costes, A., Molitor, R., Mlecnik, B., Kirilovsky, A., Nilsson, M., Damotte, D., et al. (2005). Effector memory T cells, early metastasis, and survival in colorectal cancer. *N Engl J Med* 353, 2654-2666.
5. Chen, D.S., and Mellman, I. (2013). Oncology meets immunology: the cancer-immunity cycle. *Immunity* 39, 1-10.
6. Dunn, G.P., Bruce, A.T., Ikeda, H., Old, L.J., and Schreiber, R.D. (2002). Cancer immunoediting: from immunosurveillance to tumor escape. *Nat Immunol* 3, 991-998.
7. Qin, Z., and Blankenstein, T. (2004). A cancer immunosurveillance controversy. *Nat Immunol* 5, 3-4; author reply 4-5.
8. Shankaran, V., Ikeda, H., Bruce, A.T., White, J.M., Swanson, P.E., Old, L.J., and Schreiber, R.D. (2001). IFN γ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. *Nature* 410, 1107-1111.
9. Smyth, M.J., Thia, K.Y., Cretney, E., Kelly, J.M., Snook, M.B., Forbes, C.A., and Scalzo, A.A. (1999). Perforin is a major contributor to NK cell control of tumor metastasis. *J Immunol* 162, 6658-6662.
10. van den Broek, M.E., Kagi, D., Ossendorp, F., Toes, R., Vamvakas, S., Lutz, W.K., Melief, C.J., Zinkernagel, R.M., and Hengartner, H. (1996). Decreased tumor surveillance in perforin-deficient mice. *J Exp Med* 184, 1781-1790.
11. Boon, T., Cerottini, J.C., Van den Eynde, B., van der Bruggen, P., and Van Pel, A. (1994). Tumor antigens recognized by T lymphocytes. *Annu Rev Immunol* 12, 337-365.
12. Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pages, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006). Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. *Science* 313, 1960-1964.
13. Mahmoud, S.M., Paish, E.C., Powe, D.G., Macmillan, R.D., Grainge, M.J., Lee, A.H., Ellis, I.O., and Green, A.R. (2011). Tumor-infiltrating CD8 $^{+}$ lymphocytes predict clinical outcome in breast cancer. *J Clin Oncol* 29, 1949-1955.
14. Zhang, L., Conejo-Garcia, J.R., Katsaros, D., Gimotty, P.A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M.N., et al. (2003). Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. *N Engl J Med* 348, 203-213.
15. Eyles, J., Puau, A.L., Wang, X., Toh, B., Prakash, C., Hong, M., Tan, T.G., Zheng, L., Ong, L.C., Jin, Y., et al. (2010). Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. *J Clin Invest* 120, 2030-2039.
16. Lengagne, R., Graff-Dubois, S., Garcette, M., Renia, L., Kato, M., Guillet, J.G., Engelhard, V.H., Avril, M.F., Abastado, J.P., and Prevost-Blondel, A. (2008). Distinct role for CD8 T cells toward cutaneous tumors and visceral metastases. *J Immunol* 180, 130-137.
17. Lopez-Soto, A., Gonzalez, S., Smyth, M.J., and Galluzzi, L. (2017). Control of Metastasis by NK Cells. *Cancer Cell* 32, 135-154.
18. Smyth, M.J., Kelly, J.M., Baxter, A.G., Korner, H., and Sedgwick, J.D. (1998). An essential role for tumor necrosis factor in natural killer cell-mediated tumor rejection in the peritoneum. *J Exp Med* 188, 1611-1619.
19. Smyth, M.J., Thia, K.Y., Street, S.E., Cretney, E., Trapani, J.A., Taniguchi, M., Kawano, T., Pelikan, S.B., Crowe, N.Y., and Godfrey, D.I. (2000). Differential tumor surveillance by natural killer (NK) and NKT cells. *J Exp Med* 191, 661-668.
20. Takeda, K., Hayakawa, Y., Smyth, M.J., Kayagaki, N., Yamaguchi, N., Kakuta, S., Iwakura, Y., Yagita, H., and Okumura, K. (2001). Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. *Nat Med* 7, 94-100.
21. Coca, S., Perez-Piqueras, J., Martinez, D., Colmenarejo, A., Saez, M.A., Vallejo, C., Martos, J.A., and Moreno, M. (1997). The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. *Cancer* 79, 2320-2328.
22. Ishigami, S., Natsugoe, S., Tokuda, K., Nakajo, A., Che, X., Iwashige, H., Aridome, K., Hokita, S., and Aikou, T. (2000). Prognostic value of intratumoral natural killer cells in gastric carcinoma. *Cancer* 88, 577-583.
23. Benyon, R.C., Bissonnette, E.Y., and Befus, A.D. (1991). Tumor necrosis factor-alpha dependent

- cytotoxicity of human skin mast cells is enhanced by anti-IgE antibodies. *J Immunol* **147**, 2253-2258.
24. Carretero, R., Sektioglu, I.M., Garbi, N., Salgado, O.C., Beckhove, P., and Hammerling, G.J. (2015). Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. *Nat Immunol* **16**, 609-617.
 25. Cerwenka, A., and Lanier, L.L. (2016). Natural killer cell memory in infection, inflammation and cancer. *Nat Rev Immunol* **16**, 112-123.
 26. Chao, M.P., Majeti, R., and Weissman, I.L. (2011). Programmed cell removal: a new obstacle in the road to developing cancer. *Nat Rev Cancer* **12**, 58-67.
 27. Katano, M., and Torisu, M. (1982). Neutrophil-mediated tumor cell destruction in cancer ascites. *Cancer* **50**, 62-68.
 28. Flavell, R.A., Sanjabi, S., Wrzesinski, S.H., and Licona-Limon, P. (2010). The polarization of immune cells in the tumour environment by TGFbeta. *Nat Rev Immunol* **10**, 554-567.
 29. Fridlender, Z.G., Sun, J., Kim, S., Kapoor, V., Cheng, G., Ling, L., Worthen, G.S., and Albelda, S.M. (2009). Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. *Cancer Cell* **16**, 183-194.
 30. Keirsse, J., Van Damme, H., Van Ginderachter, J.A., and Laoui, D. (2017). Exploiting tumor-associated dendritic cell heterogeneity for novel cancer therapies. *J Leukoc Biol* **102**, 317-324.
 31. Mantovani, A., Sozzani, S., Locati, M., Allavena, P., and Sica, A. (2002). Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. *Trends Immunol* **23**, 549-555.
 32. Ondondo, B., Jones, E., Godkin, A., and Gallimore, A. (2013). Home sweet home: the tumor microenvironment as a haven for regulatory T cells. *Front Immunol* **4**, 197.
 33. Fleming, V., Hu, X., Weber, R., Nagibin, V., Groth, C., Altevogt, P., Utikal, J., and Umansky, V. (2018). Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression. *Front Immunol* **9**, 398.
 34. Templeton, A.J., McNamara, M.G., Seruga, B., Vera-Badillo, F.E., Aneja, P., Ocana, A., Leibowitz-Amit, R., Sonpavde, G., Knox, J.J., Tran, B., et al. (2014). Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. *J Natl Cancer Inst* **106**, dju124.
 35. Campbell, M.J., Tonlaar, N.Y., Garwood, E.R., Huo, D., Moore, D.H., Khrantsov, A.I., Au, A., Baehner, F., Chen, Y., Malaka, D.O., et al. (2011). Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. *Breast Cancer Res Treat* **128**, 703-711.
 36. Steidl, C., Lee, T., Shah, S.P., Farinha, P., Han, G., Nayar, T., Delaney, A., Jones, S.J., Iqbal, J., Weisenburger, D.D., et al. (2010). Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. *N Engl J Med* **362**, 875-885.
 37. Mishalian, I., Bayuh, R., Levy, L., Zolotarov, L., Michaeli, J., and Fridlender, Z.G. (2013). Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression. *Cancer Immunol Immunother* **62**, 1745-1756.
 38. Eruslanov, E.B., Bhojnarawala, P.S., Quatromoni, J.G., Stephen, T.L., Ranganathan, A., Deshpande, C., Akimova, T., Vachani, A., Litzky, L., Hancock, W.W., et al. (2014). Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. *J Clin Invest* **124**, 5466-5480.
 39. Gentles, A.J., Newman, A.M., Liu, C.L., Bratman, S.V., Feng, W., Kim, D., Nair, V.S., Xu, Y., Khuong, A., Hoang, C.D., et al. (2015). The prognostic landscape of genes and infiltrating immune cells across human cancers. *Nat Med* **21**, 938-945.
 40. Coffelt, S.B., Wellenstein, M.D., and de Visser, K.E. (2016). Neutrophils in cancer: neutral no more. *Nat Rev Cancer* **16**, 431-446.
 41. Casbon, A.J., Reynaud, D., Park, C., Khuc, E., Gan, D.D., Schepers, K., Passegue, E., and Werb, Z. (2015). Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils. *Proc Natl Acad Sci U S A* **112**, E566-575.
 42. Kowanetz, M., Wu, X., Lee, J., Tan, M., Hagenbeek, T., Qu, X., Yu, L., Ross, J., Korsisaari, N., Cao, T., et al. (2010). Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes. *Proc Natl Acad Sci U S A* **107**, 21248-21255.
 43. Kitamura, T., Qian, B.Z., and Pollard, J.W. (2015). Immune cell promotion of metastasis. *Nat Rev Immunol* **15**, 73-86.
 44. Coffelt, S.B., Kersten, K., Doornebal, C.W., Weiden, J., Vrijland, K., Hau, C.S., Versteegen, N.J.M., Ciampricotti, M., Hawinkels, L., Jonkers, J., and de Visser, K.E. (2015). IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis. *Nature* **522**, 345-348.
 45. Wu, W.C., Sun, H.W., Chen, H.T., Liang, J., Yu, X.J., Wu, C., Wang, Z., and Zheng, L. (2014).

- Circulating hematopoietic stem and progenitor cells are myeloid-biased in cancer patients. *Proc Natl Acad Sci U S A* **111**, 4221-4226.
46. Erez, N., Truitt, M., Olson, P., Arron, S.T., and Hanahan, D. (2010). Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF- κ B-Dependent Manner. *Cancer Cell* **17**, 135-147.
 47. Tauriello, D.V.F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibaiza, S., Canellas, A., Hernando-Mombalona, X., et al. (2018). TGF β drives immune evasion in genetically reconstituted colon cancer metastasis. *Nature* **554**, 538-543.
 48. DeNardo, D.G., Barreto, J.B., Andreu, P., Vasquez, L., Tawfik, D., Kolhatkar, N., and Coussens, L.M. (2009). CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. *Cancer Cell* **16**, 91-102.
 49. Gabrilovich, D. (2004). Mechanisms and functional significance of tumour-induced dendritic-cell defects. *Nat Rev Immunol* **4**, 941-952.
 50. Almand, B., Resser, J.R., Lindman, B., Nadaf, S., Clark, J.I., Kwon, E.D., Carbone, D.P., and Gabrilovich, D.I. (2000). Clinical significance of defective dendritic cell differentiation in cancer. *Clin Cancer Res* **6**, 1755-1766.
 51. Ghiringhelli, F., Puig, P.E., Roux, S., Parcellier, A., Schmitt, E., Solary, E., Kroemer, G., Martin, F., Chauffert, B., and Zitvogel, L. (2005). Tumor cells convert immature myeloid dendritic cells into TGF- β -secreting cells inducing CD4+CD25+ regulatory T cell proliferation. *J Exp Med* **202**, 919-929.
 52. Labidi-Galy, S.I., Sisirak, V., Meeus, P., Gobert, M., Treilleux, I., Bajard, A., Combes, J.D., Faget, J., Mithieux, F., Cassagnol, A., et al. (2011). Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer. *Cancer Res* **71**, 5423-5434.
 53. Dumitriu, I.E., Dunbar, D.R., Howie, S.E., Sethi, T., and Gregory, C.D. (2009). Human dendritic cells produce TGF- β 1 under the influence of lung carcinoma cells and prime the differentiation of CD4+CD25+Foxp3+ regulatory T cells. *J Immunol* **182**, 2795-2807.
 54. Nakayamada, S., Takahashi, H., Kanno, Y., and O'Shea, J.J. (2012). Helper T cell diversity and plasticity. *Curr Opin Immunol* **24**, 297-302.
 55. Shang, B., Liu, Y., Jiang, S.J., and Liu, Y. (2015). Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. *Sci Rep* **5**, 15179.
 56. Balkwill, F., Montfort, A., and Capasso, M. (2013). B regulatory cells in cancer. *Trends Immunol* **34**, 169-173.
 57. Olkhanud, P.B., Damdinsuren, B., Bodogai, M., Gress, R.E., Sen, R., Wejksza, K., Malchinkhuu, E., Wersto, R.P., and Biragyn, A. (2011). Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4(+) T cells to T-regulatory cells. *Cancer Res* **71**, 3505-3515.
 58. Wang, W.W., Yuan, X.L., Chen, H., Xie, G.H., Ma, Y.H., Zheng, Y.X., Zhou, Y.L., and Shen, L.S. (2015). CD19+CD24hiCD38hiBregs involved in downregulate helper T cells and upregulate regulatory T cells in gastric cancer. *Oncotarget* **6**, 33486-33499.
 59. Bodogai, M., Moritoh, K., Lee-Chang, C., Hollander, C.M., Sherman-Baust, C.A., Wersto, R.P., Araki, Y., Miyoshi, I., Yang, L., Trinchieri, G., and Biragyn, A. (2015). Immunosuppressive and Prometastatic Functions of Myeloid-Derived Suppressive Cells Rely upon Education from Tumor-Associated B Cells. *Cancer Res* **75**, 3456-3465.
 60. Guan, H., Lan, Y., Wan, Y., Wang, Q., Wang, C., Xu, L., Chen, Y., Liu, W., Zhang, X., Li, Y., et al. (2016). PD-L1 mediated the differentiation of tumor-infiltrating CD19(+) B lymphocytes and T cells in Invasive breast cancer. *Oncoimmunology* **5**, e1075112.
 61. Zhao, Y., Shen, M., Feng, Y., He, R., Xu, X., Xie, Y., Shi, X., Zhou, M., Pan, S., Wang, M., et al. (2018). Regulatory B cells induced by pancreatic cancer cell-derived interleukin-18 promote immune tolerance via the PD-1/PD-L1 pathway. *Oncotarget* **9**, 14803-14814.
 62. Andreu, P., Johansson, M., Affara, N.I., Pucci, F., Tan, T., Junankar, S., Korets, L., Lam, J., Tawfik, D., DeNardo, D.G., et al. (2010). Fc γ activation regulates inflammation-associated squamous carcinogenesis. *Cancer Cell* **17**, 121-134.
 63. Lu, P., Weaver, V.M., and Werb, Z. (2012). The extracellular matrix: a dynamic niche in cancer progression. *J Cell Biol* **196**, 395-406.
 64. Ghajar, C.M., and Bissell, M.J. (2008). Extracellular matrix control of mammary gland morphogenesis and tumorigenesis: insights from imaging. *Histochem Cell Biol* **130**, 1105-1118.
 65. Cox, T.R., and Ertel, J.T. (2011). Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer. *Dis Model Mech* **4**, 165-178.
 66. Gocheva, V., Wang, H.W., Gadea, B.B., Shree, T., Hunter, K.E., Garfall, A.L., Berman, T., and Joyce, J.A. (2010). IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. *Genes Dev* **24**, 241-255.
 67. Nozawa, H., Chiu, C., and Hanahan, D. (2006). Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. *Proc Natl Acad Sci U S A* **103**,

- 12493-12498.
68. Ribatti, D., Vacca, A., Ria, R., Marzullo, A., Nico, B., Filotico, R., Roncali, L., and Dammacco, F. (2003). Neovascularisation, expression of fibroblast growth factor-2, and mast cells with tryptase activity increase simultaneously with pathological progression in human malignant melanoma. *Eur J Cancer* *39*, 666-674.
 69. Ou, Z., Wang, Y., Liu, L., Li, L., Yeh, S., Qi, L., and Chang, C. (2015). Tumor microenvironment B cells increase bladder cancer metastasis via modulation of the IL-8/androgen receptor (AR)/MMPs signals. *Oncotarget* *6*, 26065-26078.
 70. Acuff, H.B., Carter, K.J., Fingleton, B., Gorden, D.L., and Matrisian, L.M. (2006). Matrix metalloproteinase-9 from bone marrow-derived cells contributes to survival but not growth of tumor cells in the lung microenvironment. *Cancer Res* *66*, 259-266.
 71. Coussens, L.M., Tinkle, C.L., Hanahan, D., and Werb, Z. (2000). MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. *Cell* *103*, 481-490.
 72. Putz, E.M., Mayfosh, A.J., Kos, K., Barkauskas, D.S., Nakamura, K., Town, L., Goodall, K.J., Yee, D.Y., Poon, I.K., Baschuk, N., et al. (2017). NK cell heparanase controls tumor invasion and immune surveillance. *J Clin Invest* *127*, 2777-2788.
 73. Alitalo, K., Tammela, T., and Petrova, T.V. (2005). Lymphangiogenesis in development and human disease. *Nature* *438*, 946-953.
 74. Ribatti, D., and Crivellato, E. (2009). Immune cells and angiogenesis. *J Cell Mol Med* *13*, 2822-2833.
 75. Esposito, I., Menicagli, M., Funel, N., Bergmann, F., Boggi, U., Mosca, F., Bevilacqua, G., and Campani, D. (2004). Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma. *J Clin Pathol* *57*, 630-636.
 76. Leek, R.D., Lewis, C.E., Whitehouse, R., Greenall, M., Clarke, J., and Harris, A.L. (1996). Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. *Cancer Res* *56*, 4625-4629.
 77. Yano, H., Kinuta, M., Tateishi, H., Nakano, Y., Matsui, S., Monden, T., Okamura, J., Sakai, M., and Okamoto, S. (1999). Mast cell infiltration around gastric cancer cells correlates with tumor angiogenesis and metastasis. *Gastric Cancer* *2*, 26-32.
 78. Zidlik, V., Brychtova, S., Uvirova, M., Ziak, D., and Dvorackova, J. (2015). The changes of angiogenesis and immune cell infiltration in the intra- and peri-tumoral melanoma microenvironment. *Int J Mol Sci* *16*, 7876-7889.
 79. Paduch, R. (2016). The role of lymphangiogenesis and angiogenesis in tumor metastasis. *Cell Oncol (Dordr)* *39*, 397-410.
 80. Mazzone, M., Dettori, D., de Oliveira, R.L., Loges, S., Schmidt, T., Jonckx, B., Tian, Y.M., Lanahan, A.A., Pollard, P., de Almodovar, C.R., et al. (2009). Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. *Cell* *136*, 839-851.
 81. Hamzah, J., Jugold, M., Kiessling, F., Rigby, P., Manzur, M., Marti, H.H., Rabie, T., Kaden, S., Grone, H.J., Hammerling, G.J., et al. (2008). Vascular normalization in Rgs5-deficient tumours promotes immune destruction. *Nature* *453*, 410-414.
 82. Pugh, C.W., and Ratcliffe, P.J. (2003). Regulation of angiogenesis by hypoxia: role of the HIF system. *Nat Med* *9*, 677-684.
 83. Kumar, V., and Gabrilovich, D.I. (2014). Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment. *Immunology* *143*, 512-519.
 84. Ramanathan, M., Giladi, A., and Leibovich, S.J. (2003). Regulation of vascular endothelial growth factor gene expression in murine macrophages by nitric oxide and hypoxia. *Exp Biol Med (Maywood)* *228*, 697-705.
 85. Facciabene, A., Peng, X., Hagemann, I.S., Balint, K., Barchetti, A., Wang, L.P., Gimotty, P.A., Gils, C.B., Lal, P., Zhang, L., and Coukos, G. (2011). Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. *Nature* *475*, 226-230.
 86. Takanami, I., Takeuchi, K., and Naruke, M. (2000). Mast cell density is associated with angiogenesis and poor prognosis in pulmonary adenocarcinoma. *Cancer* *88*, 2686-2692.
 87. Pan, B., Shen, J., Cao, J., Zhou, Y., Shang, L., Jin, S., Cao, S., Che, D., Liu, F., and Yu, Y. (2015). Interleukin-17 promotes angiogenesis by stimulating VEGF production of cancer cells via the STAT3/GIV signaling pathway in non-small-cell lung cancer. *Sci Rep* *5*, 16053.
 88. Lee, S., Jilani, S.M., Nikolova, G.V., Carpizo, D., and Iruela-Arispe, M.L. (2005). Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. *J Cell Biol* *169*, 681-691.
 89. Tian, L., Goldstein, A., Wang, H., Ching Lo, H., Sun Kim, I., Welte, T., Sheng, K., Dobrolecki, L.E., Zhang, X., Putluri, N., et al. (2017). Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. *Nature* *544*, 250-254.
 90. Wyckoff, J., Wang, W., Lin, E.Y., Wang, Y., Pixley, F., Stanley, E.R., Graf, T., Pollard, J.W., Segall, J.,

- and Condeelis, J. (2004). A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. *Cancer Res* **64**, 7022-7029.
91. Green, T.L., Cruse, J.M., Lewis, R.E., and Craft, B.S. (2013). Circulating tumor cells (CTCs) from metastatic breast cancer patients linked to decreased immune function and response to treatment. *Exp Mol Pathol* **95**, 174-179.
 92. Santos, M.F., Mannam, V.K., Craft, B.S., Punecky, L.V., Sheehan, N.T., Lewis, R.E., and Cruse, J.M. (2014). Comparative analysis of innate immune system function in metastatic breast, colorectal, and prostate cancer patients with circulating tumor cells. *Exp Mol Pathol* **96**, 367-374.
 93. Deneve, E., Riethdorf, S., Ramos, J., Nocca, D., Coffy, A., Daures, J.P., Maudelonde, T., Fabre, J.M., Pantel, K., and Alix-Panabieres, C. (2013). Capture of viable circulating tumor cells in the liver of colorectal cancer patients. *Clin Chem* **59**, 1384-1392.
 94. Gul, N., Babes, L., Siegmund, K., Korthouwer, R., Bogels, M., Braster, R., Vidarsson, G., ten Hagen, T.L., Kubes, P., and van Egmond, M. (2014). Macrophages eliminate circulating tumor cells after monoclonal antibody therapy. *J Clin Invest* **124**, 812-823.
 95. Mego, M., Gao, H., Cohen, E.N., Anfossi, S., Giordano, A., Sanda, T., Fouad, T.M., De Giorgi, U., Giuliano, M., Woodward, W.A., et al. (2016). Circulating Tumor Cells (CTC) Are Associated with Defects in Adaptive Immunity in Patients with Inflammatory Breast Cancer. *J Cancer* **7**, 1095-1104.
 96. Ye, L., Zhang, F., Li, H., Yang, L., Lv, T., Gu, W., and Song, Y. (2017). Circulating Tumor Cells Were Associated with the Number of T Lymphocyte Subsets and NK Cells in Peripheral Blood in Advanced Non-Small-Cell Lung Cancer. *Dis Markers* **2017**, 5727815.
 97. Camerer, E., Qazi, A.A., Duong, D.N., Cornelissen, I., Advincula, R., and Coughlin, S.R. (2004). Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. *Blood* **104**, 397-401.
 98. Palumbo, J.S., Talmage, K.E., Massari, J.V., La Jeunesse, C.M., Flick, M.J., Kombrinck, K.W., Jiroukova, M., and Degen, J.L. (2005). Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. *Blood* **105**, 178-185.
 99. Tan, W., Zhang, W., Strasner, A., Grivnenikov, S., Cheng, J.Q., Hoffman, R.M., and Karin, M. (2011). Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. *Nature* **470**, 548-553.
 100. Steinert, G., Scholch, S., Niemietz, T., Iwata, N., Garcia, S.A., Behrens, B., Voigt, A., Kloor, M., Benner, A., Bork, U., et al. (2014). Immune escape and survival mechanisms in circulating tumor cells of colorectal cancer. *Cancer Res* **74**, 1694-1704.
 101. Konig, L., Kasimir-Bauer, S., Hoffmann, O., Bittner, A.K., Wagner, B., Manvailer, L.F., Schramm, S., Bankfalvi, A., Giebel, B., Kimmig, R., et al. (2016). The prognostic impact of soluble and vesicular HLA-G and its relationship to circulating tumor cells in neoadjuvant treated breast cancer patients. *Hum Immunol* **77**, 791-799.
 102. Gruber, I., Landenberger, N., Staebler, A., Hahn, M., Wallwiener, D., and Fehm, T. (2013). Relationship between circulating tumor cells and peripheral T-cells in patients with primary breast cancer. *Anticancer Res* **33**, 2233-2238.
 103. Cools-Lartigue, J., Spicer, J., McDonald, B., Gowing, S., Chow, S., Giannias, B., Bourdeau, F., Kubes, P., and Ferri, L. (2013). Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. *J Clin Invest* **123**, 3446-3458.
 104. Park, J., Wysocki, R.W., Amoozgar, Z., Maiorino, L., Fein, M.R., Jorns, J., Schott, A.F., Kinugasa-Katayama, Y., Lee, Y., Won, N.H., et al. (2016). Cancer cells induce metastasis-supporting neutrophil extracellular DNA traps. *Sci Transl Med* **8**, 361ra138.
 105. Spicer, J.D., McDonald, B., Cools-Lartigue, J.J., Chow, S.C., Giannias, B., Kubes, P., and Ferri, L.E. (2012). Neutrophils promote liver metastasis via Mac-1-mediated interactions with circulating tumor cells. *Cancer Res* **72**, 3919-3927.
 106. Stegner, D., Dutting, S., and Nieswandt, B. (2014). Mechanistic explanation for platelet contribution to cancer metastasis. *Thromb Res* **133 Suppl 2**, S149-157.
 107. Labelle, M., Begum, S., and Hynes, R.O. (2011). Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. *Cancer Cell* **20**, 576-590.
 108. Schumacher, D., Strlic, B., Sivaraj, K.K., Wettschureck, N., and Offermanns, S. (2013). Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor. *Cancer Cell* **24**, 130-137.
 109. Qian, B., Deng, Y., Im, J.H., Muschel, R.J., Zou, Y., Li, J., Lang, R.A., and Pollard, J.W. (2009). A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. *PLoS One* **4**, e6562.
 110. Qian, B.Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L.R., Kaiser, E.A., Snyder, L.A., and Pollard, J.W. (2011). CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis.

- Nature 475, 222-225.
111. Kitamura, T., Doughty-Shenton, D., Cassetta, L., Fragkogianni, S., Brownlie, D., Kato, Y., Carragher, N., and Pollard, J.W. (2017). Monocytes Differentiate to Immune Suppressive Precursors of Metastasis-Associated Macrophages in Mouse Models of Metastatic Breast Cancer. *Front Immunol* 8, 2004.
 112. Chen, Q., Zhang, X.H., and Massague, J. (2011). Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs. *Cancer Cell* 20, 538-549.
 113. Paget, S. (1989). The distribution of secondary growths in cancer of the breast. 1889. *Cancer Metastasis Rev* 8, 98-101.
 114. Ewing, J. (2005). *Neoplastic Diseases: A Treatise on Tumours*. W. B. Saunders Co. Ltd. *British Journal of Surgery* 16, 174-175.
 115. Fidler, I.J., and Nicolson, G.L. (1976). Organ selectivity for implantation survival and growth of B16 melanoma variant tumor lines. *J Natl Cancer Inst* 57, 1199-1202.
 116. Muller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M.E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S.N., et al. (2001). Involvement of chemokine receptors in breast cancer metastasis. *Nature* 410, 50-56.
 117. Kaplan, R.N., Riba, R.D., Zacharoulis, S., Bramley, A.H., Vincent, L., Costa, C., MacDonald, D.D., Jin, D.K., Shido, K., Kerns, S.A., et al. (2005). VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. *Nature* 438, 820-827.
 118. Liu, Y., and Cao, X. (2016). Characteristics and Significance of the Pre-metastatic Niche. *Cancer Cell* 30, 668-681.
 119. Peinado, H., Zhang, H., Matei, I.R., Costa-Silva, B., Hoshino, A., Rodrigues, G., Psaila, B., Kaplan, R.N., Bromberg, J.F., Kang, Y., et al. (2017). Pre-metastatic niches: organ-specific homes for metastases. *Nat Rev Cancer* 17, 302-317.
 120. Hoshino, A., Costa-Silva, B., Shen, T.L., Rodrigues, G., Hashimoto, A., Tesic Mark, M., Molina, H., Kohsaka, S., Di Giannatale, A., Ceder, S., et al. (2015). Tumour exosome integrins determine organotropic metastasis. *Nature* 527, 329-335.
 121. Peinado, H., Aleckovic, M., Lavotshkin, S., Matei, I., Costa-Silva, B., Moreno-Bueno, G., Hergueta-Redondo, M., Williams, C., Garcia-Santos, G., Ghajar, C., et al. (2012). Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. *Nat Med* 18, 883-891.
 122. Erler, J.T., Bennewith, K.L., Cox, T.R., Lang, G., Bird, D., Koong, A., Le, Q.T., and Giaccia, A.J. (2009). Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. *Cancer Cell* 15, 35-44.
 123. Hiratsuka, S., Watanabe, A., Sakurai, Y., Akashi-Takamura, S., Ishibashi, S., Miyake, K., Shibuya, M., Akira, S., Aburatani, H., and Maru, Y. (2008). The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. *Nat Cell Biol* 10, 1349-1355.
 124. Hiratsuka, S., Nakamura, K., Iwai, S., Murakami, M., Itoh, T., Kijima, H., Shipley, J.M., Senior, R.M., and Shibuya, M. (2002). MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. *Cancer Cell* 2, 289-300.
 125. Yamamura, Y., Asai, N., Enomoto, A., Kato, T., Mii, S., Kondo, Y., Ushida, K., Niimi, K., Tsunoda, N., Nagino, M., et al. (2015). Akt-Girdin signaling in cancer-associated fibroblasts contributes to tumor progression. *Cancer Res* 75, 813-823.
 126. Wang, D., Sun, H., Wei, J., Cen, B., and DuBois, R.N. (2017). CXCL1 Is Critical for Premetastatic Niche Formation and Metastasis in Colorectal Cancer. *Cancer Res* 77, 3655-3665.
 127. Wculek, S.K., and Malanchi, I. (2015). Neutrophils support lung colonization of metastasis-initiating breast cancer cells. *Nature* 528, 413-417.
 128. Hiratsuka, S., Watanabe, A., Aburatani, H., and Maru, Y. (2006). Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. *Nat Cell Biol* 8, 1369-1375.
 129. Clever, D., Roychoudhuri, R., Constantinides, M.G., Askenase, M.H., Sukumar, M., Klebanoff, C.A., Eil, R.L., Hickman, H.D., Yu, Z., Pan, J.H., et al. (2016). Oxygen Sensing by T Cells Establishes an Immunologically Tolerant Metastatic Niche. *Cell* 166, 1117-1131 e1114.
 130. Sceneay, J., Parker, B.S., Smyth, M.J., and Moller, A. (2013). Hypoxia-driven immunosuppression contributes to the pre-metastatic niche. *Oncoimmunology* 2, e22355.
 131. Giles, A.J., Reid, C.M., Evans, J.D., Murgai, M., Vicioso, Y., Highfill, S.L., Kasai, M., Vahdat, L., Mackall, C.L., Lyden, D., et al. (2016). Activation of Hematopoietic Stem/Progenitor Cells Promotes Immunosuppression Within the Pre-metastatic Niche. *Cancer Res* 76, 1335-1347.
 132. Gazzaniga, S., Bravo, A.I., Guglielmotti, A., van Rooijen, N., Maschi, F., Vecchi, A., Mantovani, A., Mordoh, J., and Wainstok, R. (2007). Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. *J Invest Dermatol* 127, 2031-2041.

133. Ries, C.H., Cannarile, M.A., Hoves, S., Benz, J., Wartha, K., Runza, V., Rey-Giraud, F., Pradel, L.P., Feuerhake, F., Klamann, I., et al. (2014). Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. *Cancer Cell* 25, 846-859.
134. Lin, E.Y., Nguyen, A.V., Russell, R.G., and Pollard, J.W. (2001). Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. *J Exp Med* 193, 727-740.
135. Mitchem, J.B., Brennan, D.J., Knolhoff, B.L., Belt, B.A., Zhu, Y., Sanford, D.E., Belaygorod, L., Carpenter, D., Collins, L., Piwnica-Worms, D., et al. (2013). Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. *Cancer Res* 73, 1128-1141.
136. Ruffell, B., Chang-Strachan, D., Chan, V., Rosenbusch, A., Ho, C.M., Pryer, N., Daniel, D., Hwang, E.S., Rugo, H.S., and Coussens, L.M. (2014). Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. *Cancer Cell* 26, 623-637.
137. Highfill, S.L., Cui, Y., Giles, A.J., Smith, J.P., Zhang, H., Morse, E., Kaplan, R.N., and Mackall, C.L. (2014). Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. *Sci Transl Med* 6, 237ra267.
138. Steele, C.W., Karim, S.A., Leach, J.D.G., Bailey, P., Upstill-Goddard, R., Rishi, L., Foth, M., Bryson, S., McDaid, K., Wilson, Z., et al. (2016). CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. *Cancer Cell* 29, 832-845.
139. Curiel, T.J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J.R., Zhang, L., Burow, M., et al. (2004). Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. *Nat Med* 10, 942-949.
140. Kurose, K., Ohue, Y., Wada, H., Iida, S., Ishida, T., Kojima, T., Doi, T., Suzuki, S., Isobe, M., Funakoshi, T., et al. (2015). Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients. *Clin Cancer Res* 21, 4327-4336.
141. Sun, W., Wei, F.Q., Li, W.J., Wei, J.W., Zhong, H., Wen, Y.H., Lei, W.B., Chen, L., Li, H., Lin, H.Q., et al. (2017). A positive-feedback loop between tumour infiltrating activated Treg cells and type 2-skewed macrophages is essential for progression of laryngeal squamous cell carcinoma. *Br J Cancer* 117, 1631-1643.
142. Yang, P., Li, Q.J., Feng, Y., Zhang, Y., Markowitz, G.J., Ning, S., Deng, Y., Zhao, J., Jiang, S., Yuan, Y., et al. (2012). TGF- β -miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. *Cancer Cell* 22, 291-303.
143. Karavitis, J., Hix, L.M., Shi, Y.H., Schultz, R.F., Khazaie, K., and Zhang, M. (2012). Regulation of COX2 expression in mouse mammary tumor cells controls bone metastasis and PGE2-induction of regulatory T cell migration. *PLoS One* 7, e46342.
144. Mariathasan, S., Turley, S.J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel, E.E., III, Koeppen, H., Astarita, J.L., Cubas, R., et al. (2018). TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. *Nature* 554, 544-548.
145. Kitamura, T., and Pollard, J.W. (2015). Therapeutic potential of chemokine signal inhibition for metastatic breast cancer. *Pharmacol Res* 100, 266-270.
146. Pienta, K.J., Machiels, J.P., Schrijvers, D., Alekseev, B., Shkolnik, M., Crabb, S.J., Li, S., Seetharam, S., Puchalski, T.A., Takimoto, C., et al. (2013). Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer. *Invest New Drugs* 31, 760-768.
147. Bonapace, L., Coissieux, M.M., Wyckoff, J., Mertz, K.D., Varga, Z., Junt, T., and Bentires-Alj, M. (2014). Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. *Nature* 515, 130-133.
148. Kumar, V., Donthireddy, L., Marvel, D., Condamine, T., Wang, F., Lavilla-Alonso, S., Hashimoto, A., Vonteddu, P., Behera, R., Goins, M.A., et al. (2017). Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors. *Cancer Cell* 32, 654-668 e655.
149. Swierczak, A., Cook, A.D., Lenzo, J.C., Restall, C.M., Doherty, J.P., Anderson, R.L., and Hamilton, J.A. (2014). The promotion of breast cancer metastasis caused by inhibition of CSF-1R/CSF-1 signaling is blocked by targeting the G-CSF receptor. *Cancer Immunol Res* 2, 765-776.
150. Beffinger, M., Tallon de Lara, P., Tugues, S., Vermeer, M., Montagnolo, Y., Ohs, I., Ceconi, V., Lucchiar, G., Gagliardi, A., Misljencevic, N., et al. (2018). CSF1R-dependent myeloid cells are required for NK-mediated control of metastasis. *JCI Insight* 3, e97792.
151. Pyonteck, S.M., Akkari, L., Schuhmacher, A.J., Bowman, R.L., Sevenich, L., Quail, D.F., Olson, O.C., Quick, M.L., Huse, J.T., Teijeiro, V., et al. (2013). CSF-1R inhibition alters macrophage polarization and blocks glioma progression. *Nat Med* 19, 1264-1272.
152. Shime, H., Matsumoto, M., Oshiumi, H., Tanaka, S., Nakane, A., Iwakura, Y., Tahara, H., Inoue,

- N., and Seya, T. (2012). Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors. *Proc Natl Acad Sci U S A* **109**, 2066-2071.
153. de Haas, N., de Koning, C., Spilgies, L., de Vries, I.J., and Hato, S.V. (2016). Improving cancer immunotherapy by targeting the STATE of MDSCs. *Oncoimmunology* **5**, e1196312.
 154. Kroemer, G., Galluzzi, L., and Zitvogel, L. (2016). STAT3 inhibition for cancer therapy: Cell-autonomous effects only? *Oncoimmunology* **5**, e1126063.
 155. Schaer, D.A., Budhu, S., Liu, C., Bryson, C., Malandro, N., Cohen, A., Zhong, H., Yang, X., Houghton, A.N., Merghoub, T., and Wolchok, J.D. (2013). GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability. *Cancer Immunol Res* **1**, 320-331.
 156. Kersten, K., Salvagno, C., and de Visser, K.E. (2015). Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy. *Front Immunol* **6**, 516.
 157. Wargo, J.A., Reuben, A., Cooper, Z.A., Oh, K.S., and Sullivan, R.J. (2015). Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy. *Semin Oncol* **42**, 601-616.
 158. Han, Y., Yu, Z., Wen, S., Zhang, B., Cao, X., and Wang, X. (2012). Prognostic value of chemotherapy-induced neutropenia in early-stage breast cancer. *Breast Cancer Res Treat* **131**, 483-490.
 159. Lutsiak, M.E., Semnani, R.T., De Pascalis, R., Kashmiri, S.V., Schlom, J., and Sabzevari, H. (2005). Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. *Blood* **105**, 2862-2868.
 160. Galluzzi, L., Buque, A., Kepp, O., Zitvogel, L., and Kroemer, G. (2015). Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. *Cancer Cell* **28**, 690-714.
 161. Mok, S., Koya, R.C., Tsui, C., Xu, J., Robert, L., Wu, L., Graeber, T., West, B.L., Bollag, G., and Ribas, A. (2014). Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. *Cancer Res* **74**, 153-161.
 162. Contini, P., Ghio, M., Poggi, A., Filaci, G., Indiveri, F., Ferrone, S., and Puppo, F. (2003). Soluble HLA-A,-B,-C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation. *Eur J Immunol* **33**, 125-134.
 163. Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J.C., et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med* **363**, 711-723.
 164. Overman, M.J., McDermott, R., Leach, J.L., Lonardi, S., Lenz, H.J., Morse, M.A., Desai, J., Hill, A., Axelson, M., Moss, R.A., et al. (2017). Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. *Lancet Oncol* **18**, 1182-1191.
 165. Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., Powderly, J.D., Carvajal, R.D., Sosman, J.A., Atkins, M.B., et al. (2012). Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *N Engl J Med* **366**, 2443-2454.
 166. Alexander, W. (2016). The Checkpoint Immunotherapy Revolution: What Started as a Trickle Has Become a Flood, Despite Some Daunting Adverse Effects; New Drugs, Indications, and Combinations Continue to Emerge. *P T* **41**, 185-191.
 167. Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.J., Cowey, C.L., Lao, C.D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015). Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. *N Engl J Med* **373**, 23-34.
 168. Humphries, C. (2013). Adoptive cell therapy: Honing that killer instinct. *Nature* **504**, S13-15. 10.1038/504S13a.
 169. June, C.H., O'Connor, R.S., Kawalekar, O.U., Ghassemi, S., and Milone, M.C. (2018). CAR T cell immunotherapy for human cancer. *Science* **359**, 1361-1365.
 170. Tran, E., Turcotte, S., Gros, A., Robbins, P.F., Lu, Y.C., Dudley, M.E., Wunderlich, J.R., Somerville, R.P., Hogan, K., Hinrichs, C.S., et al. (2014). Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. *Science* **344**, 641-645.
 171. Tran, E., Robbins, P.F., Lu, Y.C., Prickett, T.D., Gartner, J.J., Jia, L., Pasetto, A., Zheng, Z., Ray, S., Groh, E.M., et al. (2016). T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. *N Engl J Med* **375**, 2255-2262.
 172. Yang, J.C., and Rosenberg, S.A. (2016). Adoptive T-Cell Therapy for Cancer. *Adv Immunol* **130**, 279-294.
 173. Zacharakis, N., Chinnasamy, H., Black, M., Xu, H., Lu, Y.C., Zheng, Z., Pasetto, A., Langhan, M., Shelton, T., Prickett, T., et al. (2018). Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. *Nat Med* **24**, 724-730.
 174. Goutagny, N., and Fitzgerald, K.A. (2006). Pattern recognition receptors: an update. *Expert Rev*

- Clin Immunol 2, 569-583.
175. Goutagny, N., Estornes, Y., Hasan, U., Lebecque, S., and Caux, C. (2012). Targeting pattern recognition receptors in cancer immunotherapy. *Target Oncol* 7, 29-54.
 176. Dummer, R., Hauschild, A., Becker, J.C., Grob, J.J., Schadendorf, D., Tebbs, V., Skalsky, J., Kaehler, K.C., Moosbauer, S., Clark, R., et al. (2008). An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma. *Clin Cancer Res* 14, 856-864.
 177. Byrne, K.T., and Vonderheide, R.H. (2016). CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer. *Cell Rep* 15, 2719-2732.
 178. Vonderheide, R.H., and Glennie, M.J. (2013). Agonistic CD40 antibodies and cancer therapy. *Clin Cancer Res* 19, 1035-1043.
 179. Johnson, P., Challis, R., Chowdhury, F., Gao, Y., Harvey, M., Geldart, T., Kerr, P., Chan, C., Smith, A., Steven, N., et al. (2015). Clinical and biological effects of an agonist anti-CD40 antibody: a Cancer Research UK phase I study. *Clin Cancer Res* 21, 1321-1328.
 180. Ruter, J., Antonia, S.J., Burris, H.A., Huhn, R.D., and Vonderheide, R.H. (2010). Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors. *Cancer Biol Ther* 10, 983-993.
 181. Vonderheide, R.H., Flaherty, K.T., Khalil, M., Stumacher, M.S., Bajor, D.L., Hutnick, N.A., Sullivan, P., Mahany, J.J., Gallagher, M., Kramer, A., et al. (2007). Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. *J Clin Oncol* 25, 876-883.
 182. Kantoff, P.W., Higano, C.S., Shore, N.D., Berger, E.R., Small, E.J., Penson, D.F., Redfern, C.H., Ferrari, A.C., Dreicer, R., Sims, R.B., et al. (2010). Sipuleucel-T immunotherapy for castration-resistant prostate cancer. *N Engl J Med* 363, 411-422.
 183. van Poelgeest, M.I., Welters, M.J., van Esch, E.M., Stynenbosch, L.F., Kerpershoek, G., van Persijn van Meerten, E.L., van den Henden, M., Lowik, M.J., Berends-van der Meer, D.M., Fathors, L.M., et al. (2013). HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial. *J Transl Med* 11, 88.
 184. Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.P., Simon, P., Lower, M., Bukur, V., Tadmor, A.D., Luxemburger, U., Schrors, B., et al. (2017). Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. *Nature* 547, 222-226.
 185. Rosenberg, S.A., Yang, J.C., Topalian, S.L., Schwartzentruber, D.J., Weber, J.S., Parkinson, D.R., Seipp, C.A., Einhorn, J.H., and White, D.E. (1994). Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. *JAMA* 271, 907-913.
 186. Ahmadzadeh, M., and Rosenberg, S.A. (2006). IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. *Blood* 107, 2409-2414.
 187. Choudhry, H., Helmi, N., Abdulaal, W.H., Zeyadi, M., Zamzami, M.A., Wu, W., Mahmoud, M.M., Warsi, M.K., Rasool, M., and Jamal, M.S. (2018). Prospects of IL-2 in Cancer Immunotherapy. *Biomed Res Int* 2018, 9056173.
 188. Guillerey, C., Chow, M.T., Miles, K., Olver, S., Sceneay, J., Takeda, K., Moller, A., and Smyth, M.J. (2015). Toll-like receptor 3 regulates NK cell responses to cytokines and controls experimental metastasis. *Oncoimmunology* 4, e1027468.
 189. Romee, R., Leong, J.W., and Fehniger, T.A. (2014). Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer. *Scientifica (Cairo)* 2014, 205796.
 190. Parkhurst, M.R., Riley, J.P., Dudley, M.E., and Rosenberg, S.A. (2011). Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. *Clin Cancer Res* 17, 6287-6297.
 191. Matlung, H.L., Szilagy, K., Barclay, N.A., and van den Berg, T.K. (2017). The CD47-SIRPalpha signaling axis as an innate immune checkpoint in cancer. *Immunol Rev* 276, 145-164.
 192. Willingham, S.B., Volkmer, J.P., Gentles, A.J., Sahoo, D., Dalerba, P., Mitra, S.S., Wang, J., Contreras-Trujillo, H., Martin, R., Cohen, J.D., et al. (2012). The CD47-signal regulatory protein alpha (SIRPalpha) interaction is a therapeutic target for human solid tumors. *Proc Natl Acad Sci U S A* 109, 6662-6667.
 193. Weiskopf, K. (2017). Cancer immunotherapy targeting the CD47/SIRPalpha axis. *Eur J Cancer* 76, 100-109.